Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
42,47 USD | +0,95% | +0,62% | +0,17% |
Attività
Numero di dipendenti: 334
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 12/06/23 |
Director of Finance/CFO | 43 | 15/05/23 | |
N. Coles
CHM | Chairman | 63 | 01/12/18 |
Raymond Sanchez
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/01/19 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/05/19 |
53 | - | ||
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Scott Akamine
LAW | General Counsel | 40 | 24/05/21 |
Mark Bodenrader
AUD | Comptroller/Controller/Auditor | 51 | 01/09/19 |
Paul Burgess
PRN | Corporate Officer/Principal | 50 | 20/06/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 63 | 01/06/19 | |
Ruth McKernan
BRD | Director/Board Member | 66 | 04/12/20 |
Deval Patrick
BRD | Director/Board Member | 67 | 20/01/21 |
Marijn Dekkers
BRD | Director/Board Member | 65 | 01/09/18 |
Norbert Riedel
BRD | Director/Board Member | 66 | 01/12/18 |
N. Coles
CHM | Chairman | 63 | 01/12/18 |
Ronald Renaud
CEO | Chief Executive Officer | 55 | 12/06/23 |
Director/Board Member | 51 | 01/09/18 | |
Suneet Varma
BRD | Director/Board Member | 55 | 14/06/22 |
Deborah Baron
BRD | Director/Board Member | 55 | 20/01/21 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 181 576 482 | 76 702 134 ( 42,24 %) | 0 | 42,24 % |
Coordinate società
Cerevel Therapeutics Holdings, Inc.
222 Jacobs Street Suite 200
02141, Cambridge
+844 304 2048
http://www.cerevel.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+0,17% | 7,71 Mrd | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
+1,69% | 22,15 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,73 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione CERE
- Società Cerevel Therapeutics Holdings, Inc.